Excellent care	for everyon	e.		
Excellent care everywhere, e	very time.			



Clinical Research Ethics Application Form V.22

Project Info.

File No: Ref No : -1 Project Title: Principal Investigator: () Start Date: End Date: Keywords:

Question	Answer
Is the PI conducting research on behalf of Island	
Health or external?	
If the PI is not from Island Health, please	
provide the name of the Island Health	
collaborator. All studies must have at least one	
Island Health affiliated team member.	
If PI is from Island Health what is their	
department?	
If External Researcher, do they have Island	
Health affiliation/privileges?	
Study nickname or acronym (if applicable):	
Type of funding for this research study; if for-	
profit funded, please complete the funding tab in	
this application.	
Provide name of the funding agency,	
department or industry sponsor (clinical trials).	
For funded studies, please provide name of the	
institution where the funds will be held:	
Enter any applicable information about your	
funding which is not already included (including	
funding applied for but not yet received).	
Is the study funded by the US Department of	
Health and Human Services (DHHS)?	
If yes, please indicate which DHHS funding	
agency.	
If this submission is part of an academic	
program please provide the name of the	
institution, supervisor, and program.	

Please describe how you will disseminate the	
results of the research study. Include if and how	
you will target specific knowledge users, and	
any plans to report results back to participants.	
If participants will not receive a report of study	
results, please explain why not.	
Do you consent to being contacted by a	
member of the Island Health Research and	
Capacity Building team regarding the	
development of dissemination strategies?	
Identify where the research will be carried out at	
Island Health (hospital, department, clinical	
area, health centre, etc.).	
Name the Island Health hospital(s) involved:	
Name the Island Health health centre(s)	
involved:	
Name the Public Health Unit(s) involved:	
Will data be sent outside of Island Health?	
(transferred)	
Will the study require any non-standard devices	
to be connected to Island Health's network?	
If yes, please describe the device, its technical	
safeguards, and who will be using it.	

Project Team Info.

Principal Investigator

Prefix: Last Name: First Name: Affiliation: Position: Email: Phone1: Phone2: Fax: Primary Address: Institution: Country: Comments:

Common Questions

1. 1. How to Complete the Application

#	Question	Answer
	The Clinical Research Ethics Board	
	(CREB) reviews research that involve	
	surgery, clinical interventions, and the	
4.4	analysis of clinical data. The CREB will	
1.1	also review clinical studies involving	
	registries and/or the linkage of databases.	
	This does not include retrospective chart	
	reviews.	
1.2	Mandatory fields	
1.3	Which tabs to complete	
1.4	Who Can Submit	
1.5	Documents	
1.6	Fee For Service	
1.7	Institutional Approval	
1.8	Timelines	
1.9	After Initial Approval	

2. 2. Principal Investigator and Study Team

#	Question	Answer
	Other than the PI, list all names and their	
2.1	primary affiliation required to be on the	
2.1	Certificate of Approval (e.g. Dr. John Doe,	
	UBC)	
	Please enter any other locations where the	
	research will be conducted under this	
2.2	Research Ethics Approval (e.g., Name of	
2.2	privately owned clinic, community centre,	
	school, classroom, participant's home, in	
	the field - provide details).	
	Please confirm all research team members	
2.3	have completed the required TCPS 2	
	(2018) Tutorial.	
	Please describe any special training	
2.4	requirements or qualifications required for	
	the study team to conduct the study	

3. 3. Funding Information

#	Question	Answer
3.1	Please provide the funding title (if different	
5.1	than the project title). (N/A if not applicable)	
3.2	Please list the type of funding for this	
3.2	research study	

3.3	If Other, please describe.	
	Please provide the name of the funding	
3.4	agency, department or industry sponsor.	
	(N/A if not applicable)	
	For funded studies, please provide name of	
3.5	the institution where the funds will be held.	
	N/A if not applicable	
	Enter any applicable information about	
3.6	your funding which is not already included	
3.0	(including funding applied for but not yet	
	received).	
3.7	Is the study funded by the US Department	
3.7	of Health and Human Services (DHHS)?	
3.8	If yes, to above, please indicate which	
5.0	DHHS funding agency.	

4. 4. Conflict of Interest

#	Question	Answer
	Do the Principal Investigator, Co-	
	Investigators and/or their related parties	
	have any personal interest(s) that could	
4.1	compromise or reasonably be perceived to	
	compromise the objective conduct of the	
	research or the integrity of the data	
	generated by the study?	
	In the box below, please describe the	
4.2	conflict of interest (COI) including dollar	
	value where applicable.	
	Do any of the researchers conducting this	
	study occupy more than one role with	
	respect to potential participants (e.g. acting	
	as both a researcher and a therapist,	
4.3	health care provider, caregiver, teacher,	
4.5	advisor, consultant, supervisor, manager,	
	student, or employer, etc.) that may create	
	a real, potential, or perceived conflict of	
	interest that could affect the integrity of the	
	research?	
4.4	If yes, please describe.	
	Please advise how you propose to manage	
4.5	any actual, perceived, or potential COI	
	outlined above	
4.6	If applicable, please identify mitigation for	
	any possible 'power over' relationships.	

	Please describe the conflict of interest	
4.7	(COI) including dollar value where	
	applicable.	

5. 5. Study Type and Information

#	Question	Answer
5.1	Research Type:	
5.2	If Other, please describe:	
	If this proposal is closely linked to any	
	other proposal previously/simultaneously	
5.3	submitted, enter the Research Ethics	
0.0	Board number of that proposal and briefly	
	describe the relationship to the other	
	proposal. (N/A if not applicable)	
	Island Health sites for the study:Indicate	
	which Island Health sites for the study	
5.4	(including study team members'	
	institutional affiliations under which the	
	research is being conducted)	
	Non-Island Health sites for the study	
5.5	(including study team members'	
0.0	institutional affiliations under which this	
	research is being conducted)	
	Please enter any other locations where the	
	research will be conducted under this	
5.6	Ethics Approval (e.g. name of privately	
0.0	owned clinic, community centre, school,	
	classroom, participant's home, in the field -	
	provide details)	
	Will biological materials be collected or	
	analyzed by researchers or a research	
5.7	lab?If yes, ensure documentation regarding	
	approval is attached in Documents. (N/A if	
	not applicable)	
	Please describe any time sensitivities (e.g.	
5.8	funding or student deadline) for the	
	conduct of the study(N/A if not applicable)	
	If applicable, please explain how the data	
	will be used for commercial purpose and	
5.9	indicate if and how participants will benefit	
	from commercialization.(N/A if not	
	applicable)	

#	Question	Answer
	Are you aware of any rejection of this study	
	by any Research Ethics Board? If yes,	
6.1	please provide known details and attach	
	any available relevant documentation	
	under Attachments.	
	After reviewing the minimal risk guidance	
6.2	notes and the criteria for minimal risk, does	
	this study qualify for minimal risk review?	
6.3	Explain/justify the level of risk and group	
0.5	vulnerability reported above.	
6.4	Describe what is known about the risks of	
0.4	the proposed research for participants	
	Has the research protocol received	
6.5	independent scientific/methodological peer	
	review?	
6.6	Scientific or methodological peer review	
	details:	
	Please attached a copy of the review if	
6.7	available and/or applicable to the	
	attachments tab.	
	If the research protocol has NOT received	
6.8	any independent scientific/methodological	
	peer review, explain why no review has	
	taken place	
	9. Please describe any risks to	
6.9	researchers, including how you will mitigate	
	the risks (e.g. injury, emotional distress,	
	economic, etc.)	

7. 7. Summary of Study and Recruitment

#	Question	Answer
	Study summary - Summarize the research	
7.1	proposal: Purpose, Hypothesis,	
/.1	Justification, Objectives, Research Design,	
	and Statistical Analysis.	
	Inclusion Criteria: Describe the participants	
	being selected for this study. List the	
	criteria for their inclusion, and justify the	
7.2	grounds for their inclusion. For research	
	involving human pluripotent stem cells,	
	provide a detailed description of the stem	
	cells being used in the research.	

	Exclusion Criteria: Describe which potential	
	participants will be excluded from	
7.3	participation, List the criteria for their	
	exclusion, and justify the grounds for their	
	exclusion.	
	Provide a detailed description of the	
	method of recruitment for the local (Island	
7.4	Health) sites. For example, describe who	
	will contact prospective participants and by	
	what means this will be done.	
	Recruitment of Normal/Control	
	ParticipantsDescribe how prospective	
7.5	normal/control participants will be	
	identified, contacted, and recruited, if the	
	method differs from the above.	
	Use of records: If existing records (e.g.	
	health records, clinic databases,	
	registration details, etc.) will be used to	
7.6	IDENTIFY potential participants, please	
	describe how permission to access the	
	information, and to collect and use the	
	information, will be obtained.	
7.7	Summary of Procedures	
	If deception will be used, please provide a	
	thorough justification, the anticipated	
7.8	impacts on your participants once they	
	learn of the deception, and describe the	
	plans to debrief participants at the end of	
	the study:	

8. 8. Participant Information and Consent Process

#	Question	Answer
8.1	How much time will a participant be asked	
0.1	to dedicate to the study?	
	How much time will Normal/Control	
8.2	participants be asked to dedicate to the	
	study?	
	Describe what is known about the	
8.3	risks/harms of the proposed research for	
	participants.	
	Describe any potential benefits to the	
8.4	participant that could arise from his or her	
	participation in the proposed research.	

	Are there any caste participants can	
	Are there any costs participants can	
	reasonably be expected to incur in order to	
8.5	participate (e.g. transportation, parking,	
	child care, etc.? Specify what they are and	
	whether or not these can be fully	
	reimbursed. If not, provide a justification.	
	Describe any remuneration	
	(payments/incentives/gifts-in-kind) to be	
8.6	offered to participants. Provide full details	
	for the amounts, form of payment, payment	
	schedules, and value of the gifts-in-kind.	
	Obtaining Consent - Please specify:a) Who	
	will explain the consent form,b) who will	
	consent participants,c) details of where the	
8.7	consent will be obtained and under what	
	circumstances, andd) the relationship	
	between the person obtaining consent and	
	the participant.	
	Waiver/Alteration of Consent: If you are	
	asking for a waiver or an alteration of the	
	requirement for participant informed	
8.8	consent please justify the waiver or	
	alteration and confirm that the study meets	
	the criteria below in yellow box. Ensure you	
	address each criterion individually.	
	If you are asking for a waiver or an	
	alteration of the requirement for participant	
	informed consent in individual medical	
	emergencies, please justify the waiver or	
8.9	alteration and explain how the study meets	
	all the criteria. Ensure that your address	
	each criteria individually. Include the	
	corresponding letter (a, b, c, d, e, f) before	
	each answer	
	How long after being provided with detailed	
	information about the study will the	
8.10	participant have to decide whether or not to	
	participate? Provide your rationale for the	
	amount of time given.	
	Will every participant have the capacity to	
8.11	give fully informed consent on their own	
	behalf?	
0.40	If no, please provide the details of the	
8.12	nature of the incapacity	

	If a participant does not have the capacity	
0.40		
8.13	to give fully informed consent, who will	
	consent on their behalf?	
	If a participant does not have the capacity	
8.14	to give fully informed consent, will they be	
	able to give assent to participate?	
	If Yes, explain how assent will be sought.	
8.15	Please be sure to attach copies of the	
	assent form under the Attachments tab.	
	Describe any situation in which the	
8.16	demonstration of ongoing consent for this	
0.10	research might be appropriate, and how	
	this would take place.	
	What provisions are planned for	
	participants, or those consenting on a	
8.17	participant's behalf, to have special	
8.17	assistance, if needed, during the consent	
	process (e.g., consent forms in Braille, or in	
	languages other than English).	
	Describe any restrictions regarding the	
	disclosure of information to research	
8.18	participants (during or at the end of the	
0.10	study) that the funder/sponsor has placed	
	on investigators, including those related to	
	the publication of results.	
	Communication of study results: Indicate	
8.19	plans for communicating study results to	
	participants.	

9. 9. Number of Participant and Regulatory Approvals/ ...

#	Question	Answer
	Other Study Sites Is this research being	
9.1	conducted at any sites other than those	
9.1	selected under Section 4 of this	
	submission, including world-wide	
9.2	If yes, please list the other sites below:	
	Is this study being submitted for ethical	
9.3	approval to any other Research Ethics	
9.5	Boards covered the by this RISe	
	submission, including world wide?	
	If yes, please provide the name of the	
9.4	REB(s) and if available, contact	
	information.	

	Number of ParticipantsHow many	
9.5	participants (including controls) will be	
	enrolled in the entire study (world wide)?	
	How many participants (including controls)	
9.6	will be enrolled at the institutions covered	
	by this Research Ethics Approval?	
9.7	Of these, how many are controls?	
	Please enter any additional comments. If	
	your study does not involve enrollment of	
9.8	human participants, please enter the	
	number of records or samples to be	
	obtained:	
	Drug approvals Enter the generic name	
	of any investigational drug(s) not yet	
9.9	approved or any marketed drug(s) used	
	outside of its approved indication.	
	Marketed DrugsEnter the name of any	
9.10	marketed drug(s) used within its approved	
	indication.	
	Natural and Non-Prescription Health	
9.11	Products	
	Experimental Devices Enter the name of	
	any new investigational devices, or	
9.12	marketed devices used in experimental	
	mode, that will be used outside of their	
	approved indication.	
	Health Canada Regulatory Approvals Is	
0.40	this study a clinical trial or investigational	
9.13	test requiring Health Canada regulatory	
	approval.	
9.14	If Yes, please check all that apply:	
	Name the sponsor/institution/investigator	
	responsible for filing a Clinical Trial	
9.15	Application (CTA) or Investigational Testing	
	Authorization (ITA) with Health Canada or	
	Other.	
	Details of the Health Canada Regulatory	
0.16	ApprovalsA copy of the approval (NOL,	
9.16	ITA, NOA) must also be attached in	
	Attachments.	
9.17	Name of Regulatory Agency:	
9.18	Date of Approval:	
9.19	Date of Pending Application:	
9.20	Health Canada NOL Control Number:	

	Stem Cell Research Does this research	
	fall within the categories of pluripotent stem	
9.21	cell research that need to be submitted to	
	the CIHR Stem Cell Oversight Committee	
	(SCOC)?	
9.22	If yes, provide details	
	Registration for Publication of Clinical	
9.23	Trials Does this clinical study fall within	
9.23	the definition stated on the yellow box (in	
	the guidelines)?	

10. 10. Number of Participants and Locations for Clini ...

#	Question	Answer
	Does this research focus on Indigenous	
10.1	peoples, communities or organizations? If	
	no, please skip to the next tab.	
	Will the research be conducted on	
	Indigenous reserves, Métis settlement(s),	
10.2	or lands governed under a self-government	
	agreement or an Inuit or First Nations land	
	claims agreement?	
	Do any of the criteria for participation	
	include membership in an Indigenous	
10.3	community, group of communities, or	
	organization, including urban Indigenous	
	populations?	
	Does the research seek input from	
10.4	participants regarding a community's	
10.4	cultural heritage, artifacts, traditional	
	knowledge or unique characteristics?	
	Will Indigenous identity or membership in	
10.5	an Indigenous community be used as a	
	variable for the purposes of analysis?	
	Will the results of the research refer to	
10.6	Indigenous communities, peoples,	
	language, history or culture?	
	Community Engagement have you initiated	
10.7	or do you intend to initiate an engagement	
	process with the Indigenous collective,	
	community or communities for this study?	

	If you answered Yes to question #7 please	
	describe the process that you have	
	followed or will follow with respect to	
	community engagement. Include the role or	
10.8	position of those consulted, including their	
	names if appropriate. Attach any	
	documentation of consultations (i.e. formal	
	research agreement, letter of approval,	
	email communications, etc.) below.	
	No community consultation or engagement	
	If you answered no to question #7, briefly	
	describe why community engagement will	
10.9	not be sought and how you can conduct a	
	study that respects Indigenous	
	communities and participants in the	
	absence of community engagement.	
	If your research involves an identified	
10.10	group or community, outline the likely	
	impacts of the research on the community.	
	If applicable please describe the	
10.11	community consent process. If no	
	community consent is being sought, please	
	justify.	

11. 11. Security of Data, Research Privacy and Confide ...

#	Question	Answer
	Unblinding in an emergencyDescribe the	
11.1	provisions made to break the code of a	
''''	double-blind study in an emergency	
	situation, and indicate who has the code.	
	Data Monitoring Procedures Describe	
	data monitoring procedures while research	
11.2	is ongoing. Include details of planned	
11.2	interim analyses, Data and Safety	
	Monitoring Board, or other monitoring	
	systems.	
	Study Stoppage Describe the	
	circumstances under which the ENTIRE	
	study could be stopped early. Should this	
11.3	occur, describe what provisions would be	
	put in place to ensure that the participants	
	are fully informed of the reasons for	
	stopping the study.	

	Personal Identifiers Describe how the	
	identity of the participants will be protected	
11.4	, , , ,	
11.4	both during and after the research study,	
	including how the participants will be	
	identified on data collection forms.	
11.5	Will any personal health information or	
	personal identifiers be collected?	
	If yes above, please describe what	
11.6	personal identifying information will be	
	collected, and justify the need for it to be	
	collected.	
	If a study code/key/master list will be	
	created to link each participant to the data	
11.7	being retained, please describe who is	
	keeping the list, where, and what	
	safeguards there are to protect the list.	
	Data Access and Storage Explain who	
11.8	will have access to the data at each stage	
	of processing and analysis.	
	Indicate whether a current list of the names	
	of study personnel (including co-	
11.9	investigators and research staff) and their	
	delegated tasks will be maintained in the	
	study file.	
11.10	If a list will not be maintained, please	
11.10	explain:	
	Describe how the data will be stored (e.g.,	
	computerized files, hard copy, video-	
	recording, audio recording, personal	
11.11	electronic device, other). Please confirm	
	that any digital data will be stored on an	
	encrypted, password protected computer,	
	storage device, or hospital network server.	
44.40	Describe the safeguards in place to protect	
11.12	the confidentiality and security of the data:	
	If any data or images are to be kept on the	
11.13	Web, what precautions have been taken to	
	prevent them being copied?	
	Disposition of Study Data and	
11.14	Biospecimens please describe: what will	
	happen to the data at the end of the study:	
44.45	Please describe how long the study data	
11.15	will be retained:	

11.16Please describe when and how the data will be destroyed:11.17Please describe what plans there are for future use of the data:11.18Please describe who will have access to the data in the future and for what purpose:11.18If applicable: a) describe what will happen to the study biospecimens at the end of the studyb) how long the study biospecimens will be retained; c) where, when and how11.19the biospecimens will be destroyed; and d)	11 10
11.17Please describe what plans there are for future use of the data:11.18Please describe who will have access to the data in the future and for what purpose:If applicable: a) describe what will happen to the study biospecimens at the end of the studyb) how long the study biospecimens will be retained; c) where, when and how11.19the biospecimens will be destroyed; and d)	11.10
11.17future use of the data:11.18Please describe who will have access to the data in the future and for what purpose:If applicable: a) describe what will happen to the study biospecimens at the end of the studyb) how long the study biospecimens will be retained; c) where, when and how11.19the biospecimens will be destroyed; and d)	
11.18Please describe who will have access to the data in the future and for what purpose:If applicable: a) describe what will happen to the study biospecimens at the end of the studyb) how long the study biospecimens will be retained; c) where, when and how11.19the biospecimens will be destroyed; and d)	11.17
the data in the future and for what purpose:If applicable: a) describe what will happen to the study biospecimens at the end of the studyb) how long the study biospecimens will be retained; c) where, when and how11.19the biospecimens will be destroyed; and d)	
If applicable: a) describe what will happen to the study biospecimens at the end of the studyb) how long the study biospecimens will be retained; c) where, when and how 11.19 the biospecimens will be destroyed; and d)	11.18
studyb) how long the study biospecimens will be retained; c) where, when and how 11.19 the biospecimens will be destroyed; and d)	
will be retained; c) where, when and how 11.19 the biospecimens will be destroyed; and d)	
11.19 the biospecimens will be destroyed; and d)	
	11.19
what plans there are for future use of the	
biospecimens, including who will have	
access to the biospecimens in the future	
and for what purpose.	
Data and/or Biospecimen Transfer to Other	
Institutions Will data and/or	44.00
11.20 biospecimens be sent outside of the	11.20
Institution where it is being collected?	
If yes, please describe:a) the type of data	
to be transferred; b) who the data will be	
11.21 transferred to; c) where the data will	11.21
transferred, and; d) how the data will be	
sent.	
Data and/or Biospecimen Transfer to Other	
Institutions Will data and/or	11 22
biospecimens be sent outside of the	11.22
Institution where it is being collected?	
If yes, please describe: a) the type of data	
and/or biospecimens to be transferred; b)	
who the data and/or biospecimens will be	
11.23 transferred to; c) where the data and/or	11.23
biospecimens will be transferred (list	
institution & location); and d) how the data	
and/or biospecimens will be sent.	
Data and/or Biospecimen Transfer to	
Institution Will the researchers be	11 24
receiving data and/or biospecimens from	11.24
other sites?	

If yes, please describe:a) the type of data and/or biospecimens to be received; b) who the data and/or biospecimens will be received from; c) where the data and/or biospecimens will be received from (list institution and location); and d) how the data and/or biospecimens will be received. Data Linkage Will the data be linked to any other data source (including a biorepository)? If yes: a) identify the data set; b) how the linkage will occur; and c) explain how confidentiality regarding the shared information will be preserved. If there any plans for future use of either data or audio/video recordings please provide details, including who will have
 who the data and/or biospecimens will be received from; c) where the data and/or biospecimens will be received from (list institution and location); and d) how the data and/or biospecimens will be received. Data Linkage Will the data be linked to any other data source (including a biorepository)? If yes: a) identify the data set; b) how the linkage will occur; and c) explain how confidentiality regarding the shared information will be preserved. If there any plans for future use of either data or audio/video recordings please provide details, including who will have
11.25 received from; c) where the data and/or biospecimens will be received from (list institution and location); and d) how the data and/or biospecimens will be received. 11.26 Data Linkage Will the data be linked to any other data source (including a biorepository)? 11.27 If yes: a) identify the data set; b) how the linkage will occur; and c) explain how confidentiality regarding the shared information will be preserved. 11.28 If there any plans for future use of either data or audio/video recordings please provide details, including who will have
biospecimens will be received from (list institution and location); and d) how the data and/or biospecimens will be received. Data Linkage Will the data be linked to 11.26 Data source (including a biorepository)? If yes: a) identify the data set; b) how the linkage will occur; and c) explain how confidentiality regarding the shared information will be preserved. If there any plans for future use of either data or audio/video recordings please provide details, including who will have
institution and location); and d) how the data and/or biospecimens will be received. Data Linkage Will the data be linked to 11.26 any other data source (including a biorepository)? If yes: a) identify the data set; b) how the linkage will occur; and c) explain how confidentiality regarding the shared information will be preserved. If there any plans for future use of either data or audio/video recordings please provide details, including who will have
data and/or biospecimens will be received. 11.26 Data Linkage Will the data be linked to any other data source (including a biorepository)? 11.27 If yes: a) identify the data set; b) how the linkage will occur; and c) explain how confidentiality regarding the shared information will be preserved. 11.28 If there any plans for future use of either data or audio/video recordings please provide details, including who will have
Data Linkage Will the data be linked to 11.26 any other data source (including a biorepository)? If yes: a) identify the data set; b) how the linkage will occur; and c) explain how confidentiality regarding the shared information will be preserved. If there any plans for future use of either data or audio/video recordings please provide details, including who will have
11.26any other data source (including a biorepository)?11.27If yes: a) identify the data set; b) how the linkage will occur; and c) explain how confidentiality regarding the shared information will be preserved.11.28If there any plans for future use of either data or audio/video recordings please provide details, including who will have
biorepository)? If yes: a) identify the data set; b) how the linkage will occur; and c) explain how confidentiality regarding the shared information will be preserved. If there any plans for future use of either data or audio/video recordings please provide details, including who will have
11.27If yes: a) identify the data set; b) how the linkage will occur; and c) explain how confidentiality regarding the shared information will be preserved.11.28If there any plans for future use of either data or audio/video recordings please provide details, including who will have
11.27linkage will occur; and c) explain how confidentiality regarding the shared information will be preserved.11.28If there any plans for future use of either data or audio/video recordings please
11.27 confidentiality regarding the shared information will be preserved. If there any plans for future use of either data or audio/video recordings please provide details, including who will have
confidentiality regarding the shared information will be preserved. If there any plans for future use of either data or audio/video recordings please provide details, including who will have
If there any plans for future use of either11.28data or audio/video recordings pleaseprovide details, including who will have
11.28 data or audio/video recordings please provide details, including who will have
11.28 provide details, including who will have
provide details, including who will have
access and for what purposes, below.
Is this application for research requiring
access to clinical charts OR data from
registries or databases such as
PopDataBC or Pharmanet?
If data will be collected from health records
11.30 at Island Health, please identify who will be
accessing the health record.
Insert the date range of the charts/data to
11.31 be included in the research:

12. 12. Creation of a Research Registry or Bioreposito ...

#	Question	Answer
	Does this study involve the creation of a	
12.1	registry (data or tissue bank) with a local	
	custodian for future use in other research?	
12.2	What is the scope and purpose of the	
12.2	database / registry or biorepository?	
	What are the anticipated public and	
12.3	scientific benefits of the database, registry	
	or biorepository?	
12.4	Over what period of time will data be	
12.4	collected?	
12.5	For registry or database, what information	
12.0	source(s) are you accessing?	

	Provide specific details about the source(s)	
12.6	i.e. including the name of the database or	
	type of records, location, and owner of the	
	data.	
	For biorepositories, what are the sources of	
12.7	your biospecimens. Check all that apply.	
	All new biorepositories (biobanks)	
	associated with this study must be	
12.8	registered. Please add the registration	
	number:	
	Are you collecting personally identifiable	
10.0	information and/or will the biospecimens or	
12.9	data be linked to personally identifiable	
	information?	
	If yes to the question above, indicate the	
12.10	type of personally identifying information	
12.10	you will be collecting and include a	
	justification for its inclusion	
	If yes to the question above, how long will	
	data remain identifiable (i.e. when, if ever,	
12.11	will it be irreversibly anonymized?). Explain	
	why data needs to remain identifiable if this	
	is the case.	
	If yes to the question above, describe the	
12.12	process for removal of direct/indirect	
	identifiers, and anonymization.	
	List the individuals (who are not already	
	listed on Project Info or Project Team Info	
12.13	pages) who will have access to personally	
12.13	identifiable information at any stage in the	
	data collection or review/abstraction of the	
	data/analysis of the specimens.	
12.14	Will participants provide consent to be	
	included in a database, registry, to or have	
	their specimens included in a biorepository	
	for research purposes?	
	Specify who will explain the consent form	
12.15	and invite participants to contribute. Include	
	details of where consent will be obtained	
	and under what circumstances.	

	If you do not plan to obtain individual	
	participant informed consent, please	
12.16	provide justification for not doing so	
12.10	following the criteria outlined here. Please	
	ů – C	
	address each criterion individually. Please describe the process for a	
	participant to access and/or withdraw their	
12.17	data, including what data can be	
	withdrawn. If data cannot be amended or	
	withdrawn, please provide justification as to	
	why not.	
	What is the entity (custodian) or who is the	
12.18	person (data steward) that will have	
	responsibility for the database?	
12.19	What steps will be taken to ensure the	
	security of the data/biospecimens?	
12.20	What will be the address of the database,	
	registry or the location of the biorepository?	
	For databases and registries, describe the	
	risks associated with the possible	
12.21	disclosure of the data. Include any	
	foreseeable circumstances where	
	disclosure of identifying data may be	
	required by law.	
12.22	Will data or biospecimens be sent outside	
	of Island Health? (transferred)	
	Explain why it is necessary to send data	
	outside of the institution, and indicate what	
12.23	data will be sent, where it will be sent, who	
12.20	it will be sent to, how it will be transferred	
	(emailed, couriered, electronic encrypted	
	transfer, etc.) and where it will be stored.	
12.24	Will there by a data transfer agreement?	
	Do you plan to link the data or the	
12.25	biospecimens to another data source (e.g.,	
	database, biorepository)?	
	Identify the data set, how the linkage will	
12.26	occur, and provide a list of data items in	
	the other database.	
12.27	How long are you planning to keep the	
	data/biospecimens?	
	If the data/biospecimens will be destroyed,	
12.28	indicate the planned method for	
	erasure/destruction.	

	Will the information in the	
	database/biorepository be retained as an	
12.29	ongoing database/repository (or as part of	
	an ongoing database/repository) for future	
	research?	
	If yes to future use, provide a full	
12.30	description of the data stewardship	
	process.	
	Describe any commercial uses for which	
12.31	the data/ biospecimens may be used,	
12.31	including any disclaimers concerning	
	participant remuneration for such use.	
	If a clinical trial, does it fall within the	
12.32	definition of a clinical trial requiring	
	registration?	
	If yes above, please enter the authorized	
12.33	registry used and the clinical trial unique	
	identifier.	

13. 13. Funding

#	Question	Answer
13.1	Is this a For Profit Industry Sponsored	
13.1	Study?	
	If yes, please provide the following	
	information:Organization name;Department	
13.2	or branch;Mailing address (including City,	
13.2	Province/State, Postal/ZIP Code);Invoice to	
	be sent to the attention of;Email	
	address;Office/Cell phone number.	
13.3	Mailing address (including City,	
13.3	Province/State, Postal/ZIP Code)	
13.4	Invoice to be sent to the attention of:	
13.5	Email address:	
13.6	Office/Cell phone number:	

14. 14. Attestations

#	Question	Answer
	I attest that the information provided in this	
14.1	form is accurate and up to date at the time	
	of submission.	
	I agree to conduct the study in accordance	
14.2	with the Tri-Council Policy Statement:	
	Ethical Conduct for Research Involving	
	Humans 2nd Edition (2018)	

14.3	I agree to conduct the study in accordance	
14.5	with the REB approved documents.	
	I have read, understood, and agree to	
	abide by the Island Health policies and	
	procedures regarding the conduct of	
14.4	research: specifically Policy 25.2 Free and	
	Informed Consent in Research, Policy 25.3	
	Research Integrity Policy, and (if	
	applicable) 705 Research Finance Policy	
14.5	I agree that Island Health may conduct a	
14.5	compliance audit of this study.	
	Principal Investigator Signature: By signing	
	this application electronically, I understand	
14.6	that my electronic signature has the same	
14.0	legal effect and can be enforced in the	
	same way as a written signature. Please	
	enter your name.	

15. Please submit an operational application to pair w ...

#	Question	Answer
	If Island Health staff/physicians will be	
15.1	involved in the recruitment of participants	
15.1	for the study, please describe what the	
	involvement will entail.	
	If Island Health staff/physicians will be	
15.2	involved in any other part of the conduct of	
15.2	the study, please describe what that	
	involvement will entail.	
	Please identify all departments where	
15.3	personnel will be requested to support the	
13.3	study. If department name is unknown,	
	please identify the type of support required.	